Citations

Clear

16280 citation(s) found for "Yu, David".

Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)
Chertkow, Howard , Rockwood, Kenneth, Bartha, Robert , Beaudoin, Camille, Bélanger, Nathalie , Bellec, Pierre , Belleville, Sylvie, Bergman, Howard , Best, Sarah, Bherer, Louis , Borrie, Michael, Camicioli, Richard , Chan, Senny , Crowshoe, Lynden , Cynader, Max S., Das, Samir , Dixon, Roger A., Ducharme, Simon , Fahnestock, Margaret , Feldman, Howard , Ferland, Guylaine , Fogarty, Jennifer, Gauthier, Serge, Greenwood, Carol E., Henri-Bellemare, Charlie, Herrmann, Nathan, Itzhak, Inbal, Jacklin, Kristen , Mackenzie, Ian R. , Masellis, Mario, Maxwell, Colleen J. , McLaurin, JoAnne, Mohades, Zia, Montero‐Odasso, Manuel , Morgan, Debra, Nygaard, Haakon B. , O’Connell, Megan E. , Petersen, Ron, Pilon, Randi, Rajah, Maria Natasha, Rapoport, Mark , Roach, Pamela, Robillard, Julie M. , Rylett, R. Jane , Sadavoy, Joel , Seitz, Dallas , Walker, Jennifer , Whitehead, Victor, Wittich, Walter , Feldman, Howard H , Phillips, Natalie A. , Rockwood, Kenneth J. , Anderson, Nicole D. , Andrew, Melissa Kathryn , Bélanger, Nathalie, Belleville, Sylvie , Bethell, Jennifer , Black, Sandra E. , Carrier, Julie C , Cashman, Neil R. , Cuello, A. Claudio , Dang‐Vu, Thien Thanh , Einstein, Gillian , Evans, Alan Charles , Finger, Elizabeth C. , Fisk, John D. , Fon, Edward A , Gan‐Or, Ziv , Hogan, David B. , Hsiung, Ging‐Yuek Robin , Lanctôt, Krista L. , Lim, Andrew S. P. , McAiney, Carrie A. , McGilton, Katherine S. , McLaurin, JoAnne , Mihailidis, Alex , Morgan, Debra, Naglie, Gary , Rajah, Maria Natasha , Rogaeva, Ekaterina A. , Rosa-Neto, Pedro , George‐Hyslop, Peter St , Smith, Eric Edward , Stefanovic, Bojana , Vedel, Isabelle , Wellington, Cheryl L.

Mayo Clinic

Journal of Alzheimer’s Disease | December 5, 2024 | Volume: 102 | Issue: 3 | Pages: 535-561

10.1177/13872877241290990 | PMID 39636028 Get It

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014–2019; 2019–2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019–2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized “centrally-organized” approach to dementia research can catalyze important progress nationally and yield significant and measurable results.
Single‐port robotic transanal minimally invasive surgery (SPR‐TAMIS): another giant leap forward?
Ferrari, Davide , Peponis, Thomas , Violante, Tommaso , Ng, Jyi Cheng , Perry, William , Larson, David W. , Behm, Kevin T. , Cheng, Jyi Ng , Perry, William R , Violante, Tommaso , Larson, David W , Ferrari, Davide

Mayo Clinic

Colorectal Disease | December 5, 2024 | Volume: 27 | Issue: 1 | Pages: No page available

10.1111/codi.17252 | PMID 39635954 Get It

AbstractAimMinimally invasive transanal platforms are now the standard of care for select low‐risk rectal tumours. However, existing platforms come with persistent technical challenges. The da Vinci SP Surgical System™ offers a new alternative designed to work effectively in narrow spaces. This technology has the potential to enhance the feasibility and proximal extent of complex transanal resections. This study aimed to describe the morbidity and technical success in patients undergoing single‐port robotic transanal minimally invasive surgery (SPR‐TAMIS). Secondary outcomes include rates of local recurrence.MethodsA retrospective analysis was conducted on all patients who underwent SPR‐TAMIS at our institution between February 2019 and December 2023.ResultsThe study included 31 patients (19 men, 12 women) with a mean age of 61 ± 13.3 years. The average tumour distance from the anal verge was 10 cm. Thirty patients completed SPR‐TAMIS, with one patient requiring conversion to robotic sigmoidectomy due to location in the mid‐sigmoid colon. The mean operating time was 106 ± 42 min. Twenty‐eight out of 30 patients underwent full‐thickness excision and all but two were successfully closed. All specimens were resected intact, and margins were negative in 93.5% of cases. The average tumour size was 13 ± 34 cm2, with 13 lesions classified as adenomas and 16 as adenocarcinomas. All patients who did not undergo associated procedures were discharged on the day of surgery. Two patients experienced 30‐day morbidity. At a mean follow‐up of 18 months (± 13), no local or systemic recurrences were identified.ConclusionSPR‐TAMIS for excision of low‐risk rectal tumours is associated with high rates of technical success and low 30‐day morbidity. Further research is needed to compare SPR‐TAMIS with other techniques to determine potential advantages over current transanal platforms.
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Cloyd, Jordan M. , Sarna, Angela, Arango, Matthew J. , Bates, Susan E. , Bloomston, Mark, Ferrone, Cristina R., Gambino, Patricia, Goenka, Ajit H. , Hall, William A. , Jayaraman, Shiva , Kambadakone, Avinash, Ko, Andrew , Kooby, David A. , Krishna, Somashekar G. , Larsson, Liliana, Massarweh, Nader N. , Mikhail, Sameh , Palta, Manisha , Petzel, Maria Q. B., Philip, P. A., Mina, Daniel Santa , Sohal, Davendra , Sundaresan, Tilak , Tsai, Susan, Vreeland, Timothy J. , Walston, Steve, Wo, Jennifer Y. , Snyder, Rebecca A. , He, Jin , Tsai, Susan , Krishna, Somashekar G , Santa Mina, Daniel , Bates, Susan E , Bhutani, Manoop S. , Chung, Vincent , Dotan, Efrat , Goodman, Karyn A. , He, Jing , Hogg, Melissa E. , Katz, Matthew H. G. , Khorana, Alok A. , Koay, Eugene J. , Lee, Richard T. , Maitra, Anirban , Muzaffar, Mahvish , O’Reilly, Eileen M. , Reyngold, Marsha , Turner, Kea L. , Washington, Mary Kay , Williams, Terence M. , Snyder, Rebecca A.

Mayo Clinic

JAMA Surgery | December 4, 2024 | Volume: 160 | Issue: 2 | Pages: 172

10.1001/jamasurg.2024.5191 | PMID 39630427 Get It

Importance Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined. Objective To develop consensus best practices for delivering NT to patients with localized PDAC. Design, Setting, and Participants This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders. Main Outcome and Measures Statements that reached 75% agreement or greater were included in final consensus statements. Results Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3). Conclusions Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.
Validated approaches at mayo clinic for measuring gastric and colonic transit of solids and gastric accommodation
Abdelnaem, Nada, Camilleri, M., Bartlett, David J.

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | December 3, 2024 | Volume: 18 | Issue: 11 | Pages: 713-723

10.1080/17474124.2024.2434592 | PMID 39625697 Get It

Recruitment Strategies and Obstacles During the Zoster Eye Disease Study
Sherman, Mark D., Warner, David, Cohen, Elisabeth J. , Jiménez, Carlos López , Baratz, Keith H. , Jeng, Bennie H. , Niederer, Rachael L. , Asbell, Penny A. , Mian, Shahzad I. , Lee, Ting‐Fang , Gillespie, Colleen C.

Mayo Clinic

Cornea | December 3, 2024 | Volume: 44 | Issue: 9 | Pages: 1101-1106

10.1097/ico.0000000000003762 | PMID 39625123 Get It

Purpose: The aim of this study was to identify successful recruitment strategies and obstacles reported by principal investigators (PIs) of the Zoster Eye Disease Study (ZEDS). Methods: A web-based survey was created by a subset of ZEDS PIs and distributed to ZEDS PIs after study enrollment was closed. The survey queried investigators about recruitment strategies and obstacles, use of prophylactic oral antiviral medication, electronic medical records, telemedicine, COVID-19 effect, turnover of research staff, and recruitment outreach to minority and underserved populations. The survey allowed objective measures and free-text options. Analysis from centers with higher enrollment was compared with centers with lower enrollment to identify successful strategies and common obstacles. Results: The most frequently cited helpful strategies were participation from ophthalmologists within the PI's institution (33/63, 52%), ophthalmology resident referrals (23/63, 37%), and chart review (23/63, 37%). Travel to participating clinical center (42/63, 67%) and ongoing prophylactic use of oral systemic antiviral medication (39/63, 62%) were common obstacles. Research coordinator turnover was identified as a contributor to reduced recruitment success by 49% (31/63) of PIs and made recruitment much harder for 22% (14/63). A small number of investigators used telemedicine (18/63, 29%) and few made efforts to recruit from minority and underserved populations (10/63, 16%). Conclusions: Our survey highlights the importance of internal ophthalmologist referral, chart review, and research coordinator commitment for successful clinical trial recruitment. We discuss the impact of prophylactic use of oral antiviral medication on recruitment. Future randomized clinical trials should mobilize the helpful recruitment strategies and improve outreach to underserved populations.
Significant Microvascular Abnormalities Are Present in Autonomic Dysfunction: Results of a Prospective Study
Mumtaz, Sehreen , Arca, Karissa N., Hodge, David, Berianu, Florentina , Mumtaz, Sehreen , Majithia, Vikas , Cheshire, William P.

Mayo Clinic

No container title available | December 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5333371/v1 Get It

Abstract Purpose The prevalence and phenotype of capillaroscopic abnormalities in patients with autonomic nervous system dysfunction has not been investigated. Multiorgan involvement in dysautonomia entails abnormal vasoreactivity. We aim to corelate the diagnosis of autonomic dysfunction with certain clinical manifestations that may provide prognostic or diagnostic information using a noninvasive technique: nailfold video capillaroscopy (NVC). Methods Patients with autonomic nervous system dysfunction were recruited from rheumatology and neurology clinic with voluntary NVC procedure from 1/31/24 to 10/1/24 and a comparison with normal controls was done. Additional information recorded includes demographics, diagnosis of type of autonomic dysfunction with autonomic testing including but not limited to reflex screen, sweat test, Valsalva maneuver, nerve fiber density, electromyography (EMG), serology, history of autoimmune disease. NVC was performed on a total of 27 patients. The study was approved by the Mayo Clinic Institutional Review Board. Results Autonomic dysfunction group consisted of small fiber neuropathy (37%), orthostatic hypotension (48%), autonomic neuropathy (30%), limited autonomic neuropathy (7%), POTS (7%) and connective tissue disease (7%) amongst other types. Patient with autonomic dysfunction had statistically significant increased microhemorrhages, dilated capillaries and ramifications compared to controls. There was statistically significant correlation of age with capillary ramifications and BMI with capillary density and dilated capillaries. Conclusion Autonomic dysfunction was associated with statistically significant microvascular abnormalities compared to normal controls with a distinct NVC pattern. There was statistically significant correlation of age and BMI with microvascular abnormalities. We demonstrate diagnostic potential of NVC in autonomic dysfunction and advocate for further study of capillary structure in autonomic dysfunction.
Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Bryce, Alan H. , Beltran, Himisha , Hussain, Maha , Armstrong, Andrew J. , Calais, Jérémie , Dorff, Tanya B. , Gomella, Leonard G. , Higano, Celestia, Morris, David S. , Petrylak, Daniel P. , Reiter, Robert E. , Ryan, Charles J. , Sellinger, Scott B., Srinivas, Sandy, Taplin, Mary‐Ellen , Zhang, Tian , McKay, Rana R. , Koo, Phillip J. , Crawford, E. David , Armstrong, Andrew J , Dorff, Tanya , Morris, Michael J , Spratt, Daniel E , Tagawa, Scott T , Zhang, Tian , Bryce, Alan H , Hussain, Maha H A , Calais, Jeremie , Agarwal, Neeraj, Sartor, Oliver , Shore, Neal D. , Antonarakis, Emmanuel S. , Carducci, Michael A. , Efstathiou, Jason A. , Gleave, Martin , Higano, Celestia S. , Hope, Thomas A. , Iagaru, Andrei H. , Morgans, Alicia K. , Morris, David S., Morris, Michael J. , Rettig, Matthew B. , Spratt, Daniel E. , Tagawa, Scott T. , Yu, Evan Y.

Mayo Clinic

Cancer | December 1, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35612 | PMID 39616467 Get It

AbstractCurrent US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day‐to‐day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US‐focused expert clinical decision‐making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration‐sensitive prostate cancer; poly [ADP‐ribose] polymerase inhibitors; prostate‐specific membrane antigen radioligand therapy; and metastatic, castration‐resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
In‐field prostate cancer recurrence following radical prostatectomy and salvage radiation
Martin, Austin , Britton, Cameron J. , Fadel, Anthony , Ahmed, Mohamed E., Sharma, Vidit , Mynderse, Lance A. , Lomas, Derek J. , Woodrum, David A. , Frendl, Daniel M. , Karnes, Jeffrey , Tollefson, Matthew K. , Kwon, Eugene D., Andrews, Jack R. , Fadel, Anthony , Davis, Brian J. , Mynderse, Lance, Lomas, Derek , Woodrum, David, Karnes, Jeffrey R, Mahmoud, Ahmed , Childs, Daniel S. , Johnson, Geoffrey B.

Mayo Clinic

BJU International | November 30, 2024 | Volume: 135 | Issue: 4 | Pages: 668-674

10.1111/bju.16598 | PMID 39614716 Get It

Objective To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis‐free survival (MFS) in this unique patient population. Methods We queried a prospectively maintained PCa registry to identify men developing in‐field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy‐proven recurrent PCa or the presence of persistent positron emission tomography‐avid lesions in the prior radiation field without evidence of metastasis. Cox regression was conducted to determine predictors of MFS. Kaplan–Meier methods were used to calculate MFS, cancer‐specific survival (CSS) and overall survival (OS) for patients in three primary therapy categories: cryoablation, androgen deprivation therapy (ADT) alone, and surveillance. Results Of 4575 patients from our registry, 108 (2.3%) with IFR were identified. The median (interquartile range [IQR]) time to IFR from salvage treatment was 78 (50–126) months. A total of 29 patients (26%) were managed with cryoablation, 23 (21%) with ADT, and 28 (25%) with surveillance. The median (IQR) follow‐up was 76 (48–100) months. There were no statistically significant differences in MFS ( P = 0.67) or OS ( P = 0.07) among the three primary treatment cohorts. Patients treated with ADT or cryoablation had longer CSS compared to patients managed with surveillance ( P = 0.047). Conclusions We found that IFR may present years after completion of primary treatment for PCa. While curative management strategies may be attempted, local and distant metastatic recurrence is common and often requires systemic therapy.
Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM
Kumar, Shaji , Cohen, Inbar , Shimony, Shai, Dingli, David , Muchtar, Eli , Kapoor, Prashant , Hogan, W. Michael, Hayman, Suzanne, Kourelis, Taxiarchis , Warsame, Rahma , Vaxman, Iuliana , Kumar, Shaji K , Muchtar, E , Kapoor, Prashant , Leung, Nelson , Gonsalves, Wilson , Kourelis, Taxiarchis , Gertz, Morie A , Dingli, David , Vaxman, Iuliana , Shimony, Shai, Dispenzieri, Angela , Buadi, Francis K. , Hogan, William, Leung, Nelson , Gonsalves, Wilson I. , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | November 29, 2024 | Volume: 206 | Issue: 2 | Pages: 607-614

10.1111/bjh.19936 | PMID 39613336 Get It

Summary In 2014, the International Myeloma Working Group (IMWG) updated the criteria for diagnosing myeloma and added three additional criteria to the traditional Calcium elevation, Renal impairment, Anemia, Bone disease (CRAB) criteria, called the Sixty % marrow plama cells, Light chain ratio >60, Mri demonstates lytic lesions (SLiM) criteria (clonal bone marrow plasma cells ≥60%, involved to uninvolved free light chain ratio (FLCr) ≥100 and >1 focal lesion on magnetic resonance imaging (MRI)). We report on the outcomes of 30 patients who underwent autologous stem cell transplantation (ASCT) where therapy was initiated solely based on SLiM criteria and compared them to a matched cohort of 60 patients whose myeloma‐defining event was CRAB. The SLiM cohort had a shorter median time to neutrophil (15 vs. 16 days, p = 0.049) and platelet (15 vs. 17 days, p = 0.0004) engraftment. The 36‐month overall survival (OS) was 100% in the SLiM group and 93.27% in the control group (95% CI 83.06%–97.42%), with a trend towards longer OS in the SLiM cohort ( p = 0.065). The 36‐month progression‐free survival (PFS) was 91.61% in the SLiM (95% CI 69.93%–97.87%) and 65.95% in the control group (95% CI 52.31%–76.53%). There was no difference in the PFS between the cohorts ( p = 0.414). ASCT is efficacious and safe in MM patients transplanted only due to SLIM criteria. Early intervention in this asymptomatic cohort did not appear to result in deeper responses or better PFS compared to outcomes in symptomatic patients.
Impact of alcohol use disorder on cognition in correlation with aging: a community-based retrospective cohort study
Essa, Hesham , Min, Hoon‐Ki , Ali, D. , Lowe, Val J. , Petersen, Ronald C. , Knopman, David S. , Mester, Carly , Knopman, David S. , Ali, Dina N. , Ali, Hossam M. , Lundt, Emily S. , Mester, Carly T, Min, Hoon-Ki Paul , Ali, Hossam M , Ali, Hossam M, Ali, Dina N, Bormann, Nicholas L. , Choi, Doo‐Sup

Mayo Clinic

Alcohol and Alcoholism | November 27, 2024 | Volume: 60 | Issue: 1 | Pages: No page available

10.1093/alcalc/agae080 | PMID 39602567 Get It

Abstract Aims Excessive alcohol use is associated with an increased risk of cognitive impairment. Since increased amyloid plaque burden exacerbates cognitive decline, we sought to assess the potential impact of alcohol use disorder (AUD) on cognition, memory, and amyloid burden corresponding with age. Methods We conducted the retrospective analysis with 6036 subjects, including 269 AUD+ subjects. A four-item CAGE (C—Cutting Down, A—Annoyance by Criticism, G—Guilty Feeling, E—Eye-openers) alcohol questionnaire was given during the recruitment to determine AUD in each participant. We assessed cognitive function, focusing on memory using neuropsychological testing. For 1038 participants, including 57 AUD+ subjects, we measured amyloid burden using the 11C Pittsburgh Compound B tracer-based positron emission tomography imaging. Results AUD+ was significantly associated with lower scores of cognition and memory function relative to AUD− individuals. No significant association was found with AUD and elevated brain amyloid under the age of 65. However, further analysis showed that those aged ≥65 showed greater odds for abnormal amyloid in AUD+ compared to AUD− participants. Conclusions Our results underscore AUD as a risk factor for cognitive decline and diminished memory, particularly in aging populations. The role of AUD in brain amyloid accumulation requires further study.